For many patients with pancreatic cancer, as well as those who have undergone a pancreatectomy, or live with chronic pancreatitis or cystic fibrosis, pancreatic enzyme replacement therapy (PERT) is fundamental. However, shortages of key PERT medications like CREON/KREON and Panzytrat have impacted several EU countries, leaving patients struggling to access the treatment they need.

These supply challenges are not new. The root causes are limited production capacity and rising global demand, which has outpaced supply. While manufacturers are working to scale up production, the situation is expected to remain challenging until the second half of 2026, when improvements should start to take effect.

For pancreatic cancer patients, PERT is not optional. It is essential. A lack of it can lead to:

• Severe malnutrition, due to the body’s inability to absorb fats, proteins, and sugars.
• Digestive distress, including bloating, diarrhea, and weight loss.
• Declining overall health, which can compromise cancer treatment outcomes.
• Increased emotional and financial stress, as patients struggle to find alternatives or pay higher costs for limited supplies.

Since last year, Digestive Cancers Europe (DiCE) has been actively collaborating with patients, advocacy groups, and key stakeholders to address these shortages and advocate for long-term solutions. We have also engaged directly with pharmaceutical companies to clarify the supply situation and advocate for patients’ needs. To strengthen our efforts, we are gathering real-world data from our Member Organisations across Europe to assess the real-life impact of PERT shortages across different countries.

If you or someone in your organisation has been affected by PERT shortages, we encourage you to share your experiences. Your insights will help drive meaningful change, ensuring that every patient has access to the life-changing treatment they need. Together, we can work towards a future where no patient is left without vital medication.

Author:

Laura Ureña